Following the demerger from the healthcare arm of its business, GSK Australia is bolstering its sales arm with 30 new hires, according to “Pharma in Focus”.
Country medical director Alan Paul has also introduced a new role of clinical and patient experience managers to focus on patient voice and unmet needs.
This follows GSK’s move to become a company solely focused on speciality medicines and vaccines with a revamp of its medical affairs department.
GSK announced late last year it would split out and list Haleon as its healthcare arm, which carries brands like Sensodyne toothpaste, and Advil and Panadol painkillers.
Haleon, which listed on the London Stock Exchange (LSE) on July 18 this year, is trading around the same price as when it listed. It is described as the world’s largest consumer healthcare business with 22,800 employees (2021) and revenues of NZ$18.35 billion.